Sitryx

📍 Oxford, United Kingdom🗓 Founded 2018👥 51 employees💰 Last funded Jul 2020
Biotechnology Research🌐 sitryx.com
Website LinkedIn
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism. Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Sitryx?
Sitryx has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Sitryx last raise funding?
The most recent investment in Sitryx recorded on gritt.io was in July 2020.
When was Sitryx founded?
Sitryx was founded in 2018.
What industry is Sitryx in?
Sitryx operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Sitryx based?
Sitryx is headquartered in Oxford, United Kingdom.